R.H. Bluestein & Co’s QIAGEN NV QGENF Stock Holding History

R.H. Bluestein & Co’s Portfolio QGENF Stock Details QGENF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-30,000	Closed	-$756K	–	374
2015 Q1	$756K	Hold	30,000	–	–	0.05%	108
2014 Q4	$704K	Hold	30,000	–	–	0.04%	133
2014 Q3	$683K	Hold	30,000	–	–	0.04%	148
2014 Q2	$734K	Hold	30,000	–	–	0.04%	148
2014 Q1	$633K	Hold	30,000	–	–	0.04%	160
2013 Q4	$714K	Hold	30,000	–	–	0.04%	153
2013 Q3	$642K	Hold	30,000	–	–	0.05%	151
2013 Q2	$597K	Buy	+30,000	New	+$597K	0.05%	150

Other funds holding QGENF

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

CRM

Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

R.H. Bluestein & Co's QGENF Position: Q2 2015 in Review

R.H. Bluestein & Co sold out of QIAGEN NV (QGENF) in Q2 2015, closing a stake of 30,000 shares — an estimated $756K sold.

R.H. Bluestein & Co first reported a position in QGENF in Q2 2013 and held it in 8 quarters. The position peaked at $756K in Q1 2015. 179 funds tracked by Wall St. Rank hold QGENF as of Q2 2015.

R.H. Bluestein & Co reported no remaining QIAGEN NV position as of Q2 2015 after selling out during the quarter.
R.H. Bluestein & Co sold 30,000 QIAGEN NV shares in Q2 2015, an estimated $756K.
R.H. Bluestein & Co first reported a position in QIAGEN NV in Q2 2013 and held it in 8 quarters.
R.H. Bluestein & Co's QIAGEN NV position peaked at $756K in Q1 2015.
179 funds tracked by Wall St. Rank held QIAGEN NV as of Q2 2015.

Based on R.H. Bluestein & Co's 13F filing for Q2 2015, filed 13 Aug 2015.